Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

Published byYohanes Rachman Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas"— Presentation transcript:

1 Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas
Ze-Rui Zhao, MD, Dong-Rong Situ, MD, Rainbow W.H. Lau, MbChB., Tony S.K. Mok, MD, FRCPC, George G. Chen, PhD, Malcolm J. Underwood, MD, Calvin S.H. Ng, MD  Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Flow diagram of the study.
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 (A) Standardized differences of variables between patients who received lobectomy and segmentectomy. Red crosses symbolize differences before propensity matching and blue circles symbolize differences after propensity matching. Propensity score matching effectively reduced heterogeneity among variables between the two groups in comparison. (B) Mirror histogram of propensity scores for patients who received segmentectomy (below the horizontal line at zero) and lobectomy (above the horizontal line at zero). Matched patients are a subset of the original patient population and their volumes are highlighted in color. Matched groups have similar propensity score distributions. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Survival curves adjusted for age, sex, histological subtype, and lymph node quantity compare treatment with segmentectomy versus with lobectomy in patients with pathological stage IA adenocarcinoma (>10 and ≤20 mm) after propensity score matching for overall (A) and lung cancer–specific (B) survival. Shaded area represents the confidence limits for each group. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Multivariable Cox proportional hazards model adjusted for age, sex, histological type, and lymph node quantity for overall (A) and lung cancer–specific (B) survival by subgroup analysis in the matched population. Dashed line indicates the prespecified noninferiority margin of Blue shaded band represents the 95% confidence interval (CI) of the hazard ratio (HR) for the overall matched population. BAC, bronchioloalveolar carcinoma; Seg, segmentectomy; Lob, lobectomy. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplemental Figure 1 Unadjusted survival curves compare treatment with segmentectomy versus lobectomy in patients with pathological stage IA adenocarcinoma (>10 and ≤20 mm) for overall and lung cancer-specific survival in the entire cohort (A, B), and in the matched population (C, D). The shaded area represents the confidence limits for each group. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

7 Supplemental Figure 2 Unadjusted Survival curves compare different number of lymph nodes evaluated in patients with pathological stage IA adenocarcinoma (>10 and ≤20 mm) in the entire cohort for (A) overall and (B) lung cancer-specific survival. The shaded area represents the confidence limits for each group. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas"

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.
Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis  Nathan M. Mollberg, DO,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis  Nathan M. Mollberg, DO,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,
Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database  Daniel J. Boffa,

Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database  Daniel J. Boffa,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma  Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma  Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.
Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer  Gaurav S. Ajmani, MHS, Chi-Hsiung.

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer  Gaurav S. Ajmani, MHS, Chi-Hsiung.
Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer  Christina K. Speirs, MD, PhD, Todd.

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer  Christina K. Speirs, MD, PhD, Todd.

Similar presentations

Ads by Google